Product image of Nagilma (Metformin Hydrochloride, Linagliptin) supplied by GNH India

Nagilma

Active Ingredient:
Metformin Hydrochloride, Linagliptin
Origin:
EU

Nagilma (Metformin Hydrochloride, Linagliptin)

Metformin Hydrochloride and Linagliptin, the active ingredient in Nagilma, is a Biguanide/DPP‑4 inhibitor presented as an oral tablet for oral use. It is indicated for the treatment of type 2 diabetes mellitus in adult patients, helping to control blood glucose levels when diet and exercise are insufficient.

GNH India supplies Nagilma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable and timely logistics through global distribution networks.

Manufacturer / TM Owner

Innovis Pharma

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

  • Nagilma, a combination of metformin and linagliptin, is used in the management of type 2 diabetes mellitus.
  • Type 2 diabetes mellitus (monotherapy): lowers fasting plasma glucose and HbA1c when diet and exercise are insufficient.
  • Type 2 diabetes mellitus (add‑on to metformin): enhances post‑prandial glucose control in patients already on metformin.
  • Type 2 diabetes mellitus (combined therapy): provides synergistic glucose reduction, improving overall glycemic control.

How It Works

  • Metformin Hydrochloride reduces hepatic gluconeogenesis and increases peripheral insulin sensitivity, thereby decreasing endogenous glucose production. Linagliptin selectively inhibits the enzyme dipeptidyl peptidase‑4 (DPP‑4), which prolongs the activity of incretin hormones such as GLP‑1 and GIP, leading to glucose‑dependent insulin secretion and suppressed glucagon release. The combined actions result in improved glycemic control significantly overall without causing hypoglycemia when used alone.

Side Effects

Nagilma may cause adverse reactions, which are categorized by frequency and severity.

Common Side Effects

  • Gastrointestinal upset: nausea, abdominal discomfort, or diarrhea.
  • Headache: mild to moderate intensity.
  • Dizziness: transient episodes.
  • Metallic taste: occasional sensation.

Serious or Rare Side Effects

  • Lactic acidosis: rare but potentially fatal metabolic complication, especially in patients with renal impairment.
  • Severe hypoglycemia: may occur when combined with insulin or sulfonylureas.
  • Pancreatitis: inflammation of the pancreas presenting with abdominal pain.

Precautions & Warnings

  • When prescribing Nagilma, clinicians should consider several safety aspects.
  • Renal function: assess baseline creatinine clearance and monitor regularly.
  • Hepatic function: use with caution in patients with liver disease.
  • Lactic acidosis risk: avoid in severe renal impairment or conditions predisposing to hypoxia.
  • Pregnancy and lactation: prescribe only if potential benefit justifies risk to fetus or infant.
  • Drug interactions: review concomitant medications for agents affecting metformin or DPP‑4 inhibitor metabolism.
  • Store at ambient temperature: keep in original container, protect from moisture and heat.

Avoid Interactions

Nagilma can interact with several medicines; awareness of the interaction level guides clinical decisions.

Major Interactions (Avoid)

  • Renal contrast agents: may precipitate metformin accumulation and lactic acidosis.
  • Strong CYP3A4 inhibitors (e.g., ketoconazole): increase linagliptin plasma levels.
  • Insulin or sulfonylureas: heightened risk of hypoglycemia.
  • Diuretics (e.g., furosemide): can reduce renal clearance of metformin.
  • Alcohol excess: potentiates risk of lactic acidosis.

Moderate Interactions (Monitor Closely)

  • Beta‑blockers: may mask symptoms of hypoglycemia.
  • ACE inhibitors or ARBs: monitor renal function when combined with metformin.

Frequently Asked Questions

Nagilma is indicated for the treatment of type 2 diabetes mellitus in adult patients. It combines metformin, which improves insulin sensitivity, with linagliptin, a DPP‑4 inhibitor that enhances insulin secretion, to provide better overall glycemic control when diet and exercise alone are insufficient.

Metformin Hydrochloride lowers blood glucose primarily by reducing hepatic glucose production (gluconeogenesis) and by increasing peripheral tissue sensitivity to insulin. These actions help decrease fasting plasma glucose and improve overall glycemic balance without directly stimulating insulin release.

The specific dose of Nagilma is determined by the prescribing healthcare professional based on the individual’s clinical condition, renal function, and response to therapy. Dosage adjustments are made according to standard medical guidelines and patient monitoring.

Safety data for Nagilma in pregnancy and lactation are limited. It should only be used if the potential benefit to the mother outweighs any possible risk to the fetus or infant, and the decision must be made by a qualified healthcare provider.

To order Nagilma, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Nagilma combines two established mechanisms—metformin’s insulin‑sensitising effect and linagliptin’s DPP‑4 inhibition—offering a synergistic approach. Compared with metformin alone, it provides greater post‑prandial glucose control, and unlike sulfonylureas, it carries a lower intrinsic risk of hypoglycemia when used without other insulin‑secretagogues.

Nagilma should be stored at ambient temperature, below 25 °C, in its original packaging. Protect the tablets from moisture, direct sunlight, and excessive heat to maintain product stability throughout its shelf life.

Nagilma is taken orally, usually with a meal to reduce gastrointestinal discomfort. The tablets should be swallowed whole with a full glass of water and not crushed or chewed, unless otherwise directed by a healthcare professional.

The most serious adverse events include lactic acidosis, which is rare but potentially fatal, especially in patients with severe renal impairment, and severe hypoglycemia when combined with insulin or sulfonylureas. Prompt medical attention is required if symptoms of either condition appear.

Nagilma is contraindicated in patients with severe renal impairment (eGFR < 30 mL/min/1.73 m²), known hypersensitivity to metformin, linagliptin, or any excipients, and in individuals with a history of lactic acidosis. It should also be avoided in patients with acute or chronic metabolic acidosis.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Metformin Hydrochloride, Linagliptin

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT